Posters

Zeidner JF, Vigil CE, Lin T, et al. Phase II study incorporating a novel BH3-profiling biomarker approach of alvocidib followed by cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia (AML). European Hematology Association 23rd Annual Congress; June 14-17, 2018; Stockholm, Sweden. (Poster PDF)

Sarantopoulos J, Beg MS, Fotopoulos G, et al. A phase 1a/1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase administered daily for 21 days. 2018 American Society of Clinical Oncology Annual Meeting; June 1-5, 2018; Chicago, IL. (Abstract) (Poster PDF)

Jeon JY, Park I-K, Buelow DR, et al. TP-0903, a novel Axl inhibitor with activity in drug resistant FLT3-ITD+ AML through a mechanism that includes FLT3 inhibition. Blood. 2017;130(suppl 1):2522.

Peterson P, Kim W, Whatcott C, et al. TP-0184 inhibits ALK2/ACVR1, decreases hepcidin levels, and demonstrates activity in preclinical mouse models of functional iron deficiency. Blood. 2017;130(suppl 1):937.

Peterson P, Whatcott CJ, Bearss DJ, Warner SL, Siddiqui-Jain A. PKM2 activation suppresses cellular ROS scavenging capacity and potentiates doxorubicin antitumor activity. 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA.

Haws H, Kim W, Siddiqui-Jain A, Bearss DJ, Warner SL, Whatcott CJ. Targeting Myc in triple-negative breast cancer models through the dual inhibition of PIM kinases and CDK9. 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA.

Haws H, Livingston M, Kim W, et al. Alvocidib synergizes with venetoclax in preclinical models of multiple myeloma. European Hematology Association 22nd Annual Congress; June 22-25, 2017; Madrid, Spain.

Kim W, Haws H, Mangelson R, et al. Alvocidib synergizes with cytarabine and daunorubicin (7+3) in preclinical models of acute myeloid leukemia. European Hematology Association 22nd Annual Congress; June 22-25, 2017; Madrid, Spain.

Haws H, Livingston M, Kim W, et al. By an MCL-1–dependent mechanism, alvocidib potentiates the activity of cytarabine and mitoxantrone when administered in a time sequential regimen in AML. European Hematology Association 22nd Annual Congress; June 22-25, 2017; Madrid, Spain.

Kim W, Haws H, Peterson P, et al. TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib. American Association for Cancer Research Annual Meeting; April 1-5, 2017; Washington, DC.

Whatcott CJ, Bogenberger JM, Kim W, et al. Alvocidib potentiates the activity of venetoclax in preclinical models of acute myeloid leukemia. 58th American Society of Hematology Annual Meeting and Exposition; December 3-6, 2016; San Diego, CA.

Whatcott C, Bogenberger J, Kim W, et al. Alvocidib potentiates the activity of ABT-199 in nonclinical models of acute myeloid leukemia. European Hematology Association 21st Annual Congress; June 9-12, 2016; Copenhagen, Denmark.

Kim W, Soh S, Lee YS, et al. TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib. European Hematology Association 21st Annual Congress; June 9-12, 2016; Copenhagen, Denmark.

Kim W, Soh KK, Lee YS, et al. Targeting MCL-1 expression, through the inhibition of CDK9 and super enhancer driven transcription, offers multiple opportunities for rational drug combinations. American Association for Cancer Research Annual Meeting; April 16-20, 2016; New Orleans, LA.

Soh KK, Kim W, Lee YS, et al. AXL inhibition leads to a reversal of a mesenchymal phenotype sensitizing cancer cells to targeted agents and immuno-oncology therapies. American Association for Cancer Research Annual Meeting; April 16-20, 2016; New Orleans, LA.

Kim W, Bahr BL, Soh KK, et al. Alvocidib potentiates the activity of cytarabine and mitoxantrone through the targeting of MCL-1 when administered in a time sequential regimen in AML. 57th American Society of Hematology Annual Meeting; December 5-8, 2015; Orlando, FL.

Soh KK, Bahr BL, Bearss JJ, et al. Inhibition of Axl kinase reverses the mesenchymal phenotype in leukemic cells through the disruption of retinoid acid signaling. 57th American Society of Hematology Annual Meeting; December 5-8, 2015; Orlando, FL.

Kim W, Soh KK, Bearss JJ, et al. Alvocidib potentiates the activity of azacytidine in an MCL-1–dependent fashion. 57th American Society of Hematology Annual Meeting; December 5-8, 2015; Orlando, FL.

Dettman EJ, Warner SL, Doykan C, et al. Mitochondrial profiling in AML patients treated with an alvocidib containing regimen reveals MCL1 dependency in responder bone marrow. American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia, PA.

Bahr BL, Maughan KS, Soh KK, et al. Combination strategies to target super enhancer transcriptional activity by CDK9 and BRD4 inhibition in acute myeloid leukemia. American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia, PA.

Bearss JJ, Bahr BL, Soh KK, et al. Targeting the PIM kinases in combination with BTK inhibition is synergistic in preclinical models of B-cell malignancies. American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia, PA.

Peterson P, Kim W, Bearss JJ, et al. Targeting cancer-induced anemia with hepcidin lowering ALK2 inhibitors. American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia, PA.

Singh V, Nixon B, Gilbert TSK, et al. The use of kinome profiling to determine potential resistance pathways in pancreatic cancer cells treated with PIM kinase inhibitors. American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia, PA.